

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Rosskamp, et al**

Examiner: Khanna, Hemant

Art Unit: 1654

Application No.: 10/757,201

Filed: **January 14, 2004**

Title: **Method For Reducing Cardiovascular  
Morbidity and mortality in Prediabetic  
Patients and Patients With Type 2  
Diabetes**

**Response to the Restriction Requirement**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


Sir:

This paper is responsive to the Restriction Requirement mailed on 10/3/06.

Per Examiner's request, Applicant herein elects, without traverse, to prosecute the claims of Group I (i.e. Claims 1-7, 15-33 drawn to treating IGT and Type II diabetes).

Applicants affirm their right to file one or more divisional applications with respect to any of the non-elected subject matter.

Respectfully submitted,



Barbara E. Kurys, Reg. No.: 34,650  
Attorney/Agent for Applicant

sanofi-aventis U.S. LLC  
U.S. Patent Operations  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone: 908-231-2965  
Telefax: 908-231-2626

sanofi-aventis Docket No. USAV2003-0012 US NP